Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16104540 | 0.82 | MAPT (0.46) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7533657 | 0.82 | MAPT (0.63) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2264301 | 0.80 | CASP3 (0.48) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15544149 | 0.79 | MAPT (0.55) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18962400 | 0.76 | NPC1 (0.41) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28707774 | 0.76 | CYP3A4 (0.60) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15227597 | 0.76 | CYP3A4 (0.60) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29545275 | 0.76 | CYP3A4 (0.60) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16598981 | 0.74 | MAPT (0.54) | MAPTNPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31279173 | 0.73 | FFAR1 (0.57) | MAPTNPC1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352374-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8563746-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563746-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563746-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2011-08-11 | — | — | US | disclosed |
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2011-08-11 | — | — | US | disclosed |
| EP-2352374-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051176-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | MAPT 4011/4885NPC1 1099/4885CYP1A2 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.